NCT05150145 Radiotherapy or Observation of Liver Metastases in Small Cell Lung Cancer
| NCT ID | NCT05150145 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Guizhou Medical University |
| Condition | Radiotherapy; Complications |
| Study Type | INTERVENTIONAL |
| Enrollment | 66 participants |
| Start Date | 2021-04-30 |
| Primary Completion | 2026-03-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 66 participants in total. It began in 2021-04-30 with a primary completion date of 2026-03-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The aim of this randomized study is to investigate local tumor control,survival outcomes and complications on patients of liver metastasis in small cell lung cancer.
Eligibility Criteria
Inclusion Criteria 1. Informed consent (radiation, medication) before treatment; 2. Age 18 to 70 years old,regardless of gender; 3. Initial SCLC confirmed by histopathological or cytological examination; 4. Metastatic lesions in the distant area: included liver metastasis； 5. Physical status score ECOG: 0 to 2； 6. The expected survival time is more than 3 months; 7. Bone marrow function:hemoglobin(HGB)\>90g/L,platelet(PLT)\>100×109/L,neutrophil cell(WBC)\>1.5×109/L(\*normal value); 8. Liver function:alanine aminotransferase(ALT) and aspertate aminotransferase(AST)\<1.5 times of the upper limit of normal(ULN);Total bilirubin \<1.5ULN; 9. Renal function:Serum creatinine was lower than 1.5ULN,and the endogenous creatinine clearance rate(Ccr) is higher than 55mL/min; 10. Initial treatment (previously did not receive any thoracic radiotherapy or surgery). Exclusion Criteria: 1. patients with history of mental illness; 2. patients combined with other malignancies; 3. Active period of disease caused by bacteria, fungi or viruses; and these severe infection requiring intravenous antibiotics,antifungal or antiviral therapy; 4. Patients with serious cardiovascular disease ,including uncontrolled hypertension, unstable angina,history of myocardial infarction within the past 12 months,and severe arrhythmias. 5. Patients with poorly controlled diabetes who are judged to be unfit for chemotherapy by doctors. 6. History of hepatitis and cirrhosisi ; 7. pregnant, lactating patients; 8. Patients with poor compliance； 9. Researchers believe that it is not appropriate to participate in this test.
Contact & Investigator
Shengfa Su, doctor
PRINCIPAL INVESTIGATOR
The Affiliated Hospital Of Guizhou Medical University
Frequently Asked Questions
Who can join the NCT05150145 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 70 Years, studying Radiotherapy; Complications. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05150145 currently recruiting?
Yes, NCT05150145 is actively recruiting participants. Contact the research team at sushengfa2005@163.com for enrollment information.
Where is the NCT05150145 trial being conducted?
This trial is being conducted at Guiyang, China.
Who is sponsoring the NCT05150145 clinical trial?
NCT05150145 is sponsored by Guizhou Medical University. The principal investigator is Shengfa Su, doctor at The Affiliated Hospital Of Guizhou Medical University. The trial plans to enroll 66 participants.